Fosfomycin activity in vitro against Escherichia coli strains isolated from urine specimens

1 Carney G, Maclure M, Patrick DM, Fisher A, Stanley D, Bassett K, et al. A cluster randomized trial assessing the impact of personalized prescribing feedback on antibiotic prescribing for uncomplicated acute cystitis to family physicians. PLoS One. 2023;18(7):e0280096. Search in Google Scholar

2 Naber KG, Alidjanov JF, Blicharski T, Cerska M, Gadzinski W, Kawecki J, et al. Polish version of the acute cystitis symptom score for patients with acute uncomplicated cystitis. Cent European J Urol. 2023;76(2):144-54. Search in Google Scholar

3 Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: the current scenario and future prospects. Pathogens. 2023;12(4):623. Search in Google Scholar

4 Kuiper SG, Dijkmans AC, Wilms EB, Kamerling IMC, Burggraaf J, Stevens J, et al. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection. J Antimicrob Chemother. 2020;75(11):3278-85. Search in Google Scholar

5 Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women – a systematic review and meta-analysis. J Chemother. 2022;34(3):139-48. Search in Google Scholar

6 Wang T, Wu G, Wang J, Cui Y, Ma J, Zhu Z, et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(1):106018. Search in Google Scholar

7 Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016:2082693. Search in Google Scholar

8 Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7(2):a025262. Search in Google Scholar

9 Ito R, Mustapha MM, Tomich AD, Callaghan JD, McElheny CL, Mettus RT, et al. Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene. mBio. 2017;8:e00749-17. Search in Google Scholar

10 Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-50. Search in Google Scholar

11 Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18. Search in Google Scholar

12 EUCAST Clinical Breakpoints Tables v. 13.1, valid from 2023-06-29. [https://www.eucast.org/clinical_breakpoints] Search in Google Scholar

13 Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10(2):165. Search in Google Scholar

14 European Committee on Antimicrobial Susceptibility Testing. 2020. EUCAST fosfomycin consultation document. Search in Google Scholar

15 [ https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/2020/EUCAST_General_Consultation_on_Fosfomycon_trometamol_2020.pdf] Search in Google Scholar

16 Giske CG, Turnidge J, Cantón R, Kahlmeter G. EUCAST steering committee. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2022;60(3):e0027621. Search in Google Scholar

17 Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol. 2019;68(4):403-15. Search in Google Scholar

18 López-Sampedro I, Hernández-Chico I, Gómez-Vicente E, Expósito-Ruiz M, Navarro-Marí JM, Gutiérrez-Fernández J. Evolution of antibiotic resistance in Escherichia coli and Klebsiella pneumoniae from urine cultures. Arch Esp Urol. 2023;76(3):203-14. Search in Google Scholar

19 Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Mouton JW, Peleg AY. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. J Microbiol Methods. 2020;171:105861. Search in Google Scholar

20 Wijma RA, Huttner A, van Dun S, Kloezen W, Abbott IJ, Muller AE, et al. Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers. Int J Antimicrob Agents. 2019;54(4):435-41. Search in Google Scholar

21 Portillo-Calderón I, Ortiz-Padilla M, Rodríguez-Martínez JM, de Gregorio-Iaria B, Blázquez J, Rodríguez-Baño J, et al. Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. J Antimicrob Chemother. 2020;75(8):2066-75. Search in Google Scholar